Although statistically non-significant and limited analysis due to small sample size, our study also showed that the time on treatment was less with immunotherapy versus ROS1 targeted TKIs in ROS1+ NSCLC. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.